Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences has submitted an Investigational New Drug (IND) application to the FDA for IDE161, a potential first-in-class PARG inhibitor targeting homologous recombination deficiency in BRCA1/2-mutant breast and ovarian cancers. This submission marks a significant milestone in IDEAYA's approach to addressing the unmet medical need for patients resistant to current PARP inhibitors. The proposed clinical development plan will be discussed in an Investor R&D Day webcast on December 12, 2022.

IDEAYA Biosciences (NASDAQ: IDYA) has received Fast Track designation from the U.S. FDA for its combination therapy of darovasertib and crizotinib aimed at treating metastatic uveal melanoma (MUM). This designation facilitates an expedited regulatory process, enhancing the potential for accelerated approval. The company plans to initiate a Phase 2/3 trial in Q1 2023, pending FDA guidance. Darovasertib is also recognized as an Orphan Drug, offering IDEAYA various incentives such as tax credits and marketing exclusivity. An Investor R&D Day is scheduled for December 12, 2022.

IDEAYA Biosciences (NASDAQ: IDYA) has announced its Investor R&D Day to take place on December 12, 2022, from 8:00 am to 9:30 am ET. The event will feature key opinion leaders discussing various topics in synthetic lethality, including the Darovasertib clinical evaluation and advances in the treatment of MTAP deleted tumors. Registration is available online. The agenda aims to showcase IDEAYA’s pipeline programs and their relevance in oncology, particularly focusing on synthetic lethality therapies.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced the appointment of Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer effective November 21, 2022. Beaupre brings over 25 years of experience in clinical development, previously at Pfizer and BioSplice Therapeutics. His role will focus on expanding IDEAYA's clinical pipeline, aiming to include five clinical trials across four programs in 2023. IDEAYA specializes in synthetic lethality, targeting precision medicine oncology, with plans to leverage Beaupre's expertise to enhance its drug development efforts.

IDEAYA Biosciences (IDYA) reported a robust financial position with $393.9 million in cash and securities as of September 30, 2022, projected to support operations until 2026. The company disclosed positive Phase 2 interim clinical outcomes for darovasertib and crizotinib in metastatic uveal melanoma, targeting a potential registrational trial in Q1 2023. IDEAYA is advancing multiple clinical programs, including IDE397 and IDE161, and plans to initiate several trials in 2023. Collaboration revenue surged to $29.7 million, reflecting substantial milestones achieved in partnerships.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in key investor conferences throughout November 2022 and scheduled an Investor R&D Day for December 12, 2022. The Jefferies London Healthcare Conference will feature a fireside chat with CEO Yujiro Hata on November 15, while the Stifel Healthcare Conference will include CFO Paul Stone on November 16. The R&D Day aims to showcase insights from IDEAYA's clinical and preclinical programs, with a live webcast available for participants. For details, visit IDEAYA's investor relations page.

IDEAYA Biosciences (NASDAQ: IDYA) has announced the dosing of the first patient in two combination therapy cohorts involving IDE397, a MAT2A inhibitor, in patients with MTAP-deletion tumors. This includes combinations with pemetrexed and taxanes, presenting a potential first-in-class option. The Phase 1/2 trial, which aims to evaluate clinical efficacy, builds on positive preclinical data demonstrating robust tumor target engagement. Additionally, IDEAYA plans to assess IDE397 in collaboration with AMG 193, targeting dual signaling pathways in these tumors.

IDEAYA Biosciences (NASDAQ:IDYA) announced the closure of its public offering of 8,761,905 shares of common stock at $10.50 per share, raising approximately $92 million before underwriting costs. This includes the complete exercise of the underwriters' option for an additional 1,142,857 shares. J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities led the offering, conducted under an SEC-approved shelf registration statement. IDEAYA focuses on precision medicine in oncology, utilizing synthetic lethality in its therapeutic development.

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced a public offering of 7,619,048 shares of its common stock priced at $10.50 per share, aiming to raise approximately $80.0 million before expenses. The offering includes an option for underwriters to purchase up to an additional 1,142,857 shares. The gross proceeds could increase if the option is exercised. The transaction is expected to close on or around September 19, 2022. Key underwriters include J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities.